Divis Laboratories Share Price

    NSE
    6871
    +61.50 (0.91%)
    DIVISLAB • 01 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    44.67%

    3Y Annualised Return

    22.44%

    5Y Annualised Return

    24.89%

    The current prices are delayed, login or Open Demat Account for live prices.

    Divis Laboratories Stock Performance

    1W Return4.43
    1Y Return48.99
    Today's Low6696
    Prev. Close6,809.50
    Mkt Cap (Cr.)1,82,018.53
    1M Return3.70
    3Y Return88.49
    52-Week High6875
    Open6,828.50
    PE Ratio82.33
    6M Return12.90
    Today's High6875
    52-Week Low4395.3
    Face Value2

    Divis Laboratories Company background

    Founded in: 1990
    Managing director: Murali K Divi

    Divis Laboratories Limited is among the world leaders in the pharma industry, focusing on the production of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceuticals. The company is among the largest API manufacturers, having two manufacturing units, and a strong presence across 100 countries.

    Divis does not only support generic business, but also assists innovative pharmaceutical companies through its custom synthesis division for patented products, providing a full range of services from clinical trials to commercialization, and post-marketing activities.

    With a diverse portfolio of approximately 160 products across various therapeutic areas, Divis Laboratories is a major player in the global pharmaceutical industry, having a positive impact on the Divis Laboratories Ltd share price.

    Global Presence and Subsidiaries

    The company operates six manufacturing facilities and has a strong presence in multiple international markets. Additionally, it has two subsidiaries:

    • Divis Laboratories (USA) Inc. – Based in the United States, focusing on marketing Nutra products.

    • Divis Laboratories Europe AG – Located in Switzerland, serving European customers and expanding the company’s reach in the region.

    Research and Development (R&D) Facilities

    Divis Laboratories invests heavily in research and development, with dedicated research centers at:

    • Sanathnagar, Hyderabad – Specializing in custom synthesis, contract research for multinational companies, and future generics development.

    • Manufacturing Sites – Supporting process innovations and structural confirmations for APIs and intermediates.

    Company History and Expansion

    Divis Laboratories commenced its operations in 1990 as Divis Research Center Limited (DRC), focusing heavily on R&D. The company aimed to establish itself as a focal entity in the pharmaceutical sector through scientific innovation and expertise in Active Pharmaceutical Ingredients (APIs). During the formative years, Divis concentrated on contract research and custom synthesis for international pharmaceutical companies needing high-quality, economical services.

    The company underwent a name change in 1994 to Divis Laboratories Limited. This was due to the firm broadening its scope of business beyond research and starting high-volume manufacturing. This strategic move enabled the company to transition from being a focused research entity to a fully integrated pharmaceutical entity with manufacturing and commercial production.

    Divis made a significant move in 1995 by commissioning its first manufacturing unit (Unit I) at Choutuppal, close to Hyderabad. This was constructed to help the company’s mission of manufacturing APIs in large quantities while having a strong emphasis on research-based quality control.

    In 1997, Divis marked a major achievement by acquiring ISO 9002 certification from SGS-Yarsley, U.K. The certification acknowledged the company's dedication to international quality standards and enhanced its credibility with global pharmaceutical customers.

    By 1999, Divis advanced greatly in its manufacturing potential. And this was also solidified by the award of a Certificate of Suitability (CoS) by European Directorate for the manufacture of Naproxen. This made it easier for Divis to enter regulated markets in Europe, where it could grow its customer base and gain a name in the global pharma supply chain.

    Growth and Certifications

    The early 2000s were the years of fast growth and regulatory acknowledgment for Divis Laboratories. In 2001, the company received the OHSAS 18001 Certification from BVQI, London, for Occupational Health and Safety Management Systems.

    As the demand for its products kept growing, Divis launched a significant expansion program. In 2002, the firm started establishing its second manufacturing plant (Unit II) at Chippada, Visakhapatnam. It was part of its long-term plan to expand production capacity and meet the growing global demand for quality APIs and intermediates.

    In 2003, Divis made another giant leap towards research excellence by setting up DRC-Vizag, a dedicated research facility with a focus on basic research in niche business areas. This research facility was instrumental in creating sophisticated and high-value APIs.

    The company's growth trajectory took a major leap in 2004 when it went public with an Initial Public Offering (IPO). Divis Laboratories was successfully listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), marking a new phase in its corporate journey. The funds raised from the IPO were strategically invested in capacity expansion, infrastructure development, and research initiatives.

    Special Economic Zones (SEZ) and Infrastructure Expansion

    • In 2006:  Got the government nod to establish a sector-specific SEZ for pharmaceutical intermediates in Visakhapatnam, investing ₹200 crore.

    • Between 2007–2008: Formulated the Divis Pharma SEZ, introducing production facilities and commissioning a Nutraceuticals Manufacturing plant.

    • Between 2009–2011: Introduced new products, including custom synthesis APIs and intermediates. Also set up DSN SEZ Unit at Chippada, Visakhapatnam, with a ₹200 crore investment.

    Global Recognition

    During the period from 2012 to 2017, Divis Laboratories consolidated its position as a reliable name in the international pharma industry. The firm passed several regulatory audits successfully, reflecting its dedication to quality and regulatory compliance.

    A major highlight came in 2014 when Divis Laboratories cleared inspections from some of the world’s top regulatory authorities. The Korean Food and Drug Administration (KFDA) conducted a detailed review of the company’s manufacturing processes, ensuring they met South Korea’s strict pharmaceutical guidelines. Around the same time, COFEPRIS (Mexico) granted first-time approvals for both the Hyderabad and Visakhapatnam units, opening doors to the Latin American market.

    The US FDA completed its fourth and fifth inspections of Divis’ Units I and II, reinforcing the company’s standing as a reliable manufacturer for the US market.

    In 2016, Divis Laboratories marked a major milestone when Unit II (Visakhapatnam) was inspected by the US FDA and no observations were made. In 2017, the US FDA placed Import Alert 6640 on Unit II, temporarily suspending exports to the US. Despite this setback, Divis took quick corrective measures, setting up tighter compliance measures, and worked hard to address the concerns of the FDA.

    The same year, the company cleared inspections from Ireland's Health Products Regulatory Authority (HPRA) and Slovenia's JAZMP. These clearances further bolstered Divis' image in the European market and reiterated its position as a reliable worldwide pharmaceutical supplier.

    Infrastructure Investments and Further Expansion

    • 2018: US FDA conducted inspections at Choutuppal, Telangana.

    • 2019: Initiated two major brownfield SEZ projects with an investment of ₹1,200 crore:

    1. DCV SEZ Unit at Visakhapatnam (₹600 crore)

    2. Another SEZ project at Choutuppal, Telangana (₹600 crore)

    • 2020:
    1. Started commercial operations at both SEZ units.

    2. Began a debottlenecking project at Units I & II, investing ₹300 crore to increase production capacity.

    3. Enhanced waste treatment infrastructure at Unit II (₹150 crore investment).

    Pandemic and Post-Pandemic Outlook

    The spread of the COVID-19 pandemic during early 2020 brought tough challenges to businesses across the globe, throwing supply chains out of gear and shutting down operations. But, due to being a part of the critical pharma industry, Divis Laboratories was excused from country-wide lockdown rules in March 2020.

    As precautionary measures, Divis Laboratories set up strict safety measures to protect its workers while also maintaining business continuity. The company put in place strict hygiene practices, social distancing, and constant health checks at its production units.

    Brief Overview

    Based on its solid foundation, Divis Laboratories continues to increase its production capacity and invest in technological upgradation to cater to the growing global demand for APIs. With the pharmaceutical sector experiencing a boom in demand for major therapeutic drugs, Divis has strategically positioned itself as a major supplier of APIs for blockbuster drugs. This, in turn, has had a positive impact on the Divis Laboratories share price.

    As of 01 Jul, 2025, Divis Laboratories share price is ₹6856.5. The stock opened at ₹6828.5 and had closed at ₹6809.5 the previous day. During today’s trading session, Divis Laboratories share price moved between ₹6,696.00 and ₹6,875.00, with an average price for the day of ₹6785.50. Over the last 52 weeks, the stock has recorded a low of ₹4,395.30 and a high of ₹6,875.00. In terms of performance, Divis Laboratories share price has increased by 12.4% over the past six months and has increased by 44.67% over the last year.

    Read More
    Divis Laboratories SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹81,99,760 (+26.15%)

    Daily SIP of 25,000 would have become 81,99,760 in 1 year with a gain of 16,99,760 (+26.15%)

    View details of Market Depth

    Divis Laboratories Fundamental

    Market Cap (in crs)

    1,82,018.53

    Face Value

    2

    Turnover (in lacs)

    26,446.62

    Key Metrics

    Qtr Change %
    New 52W High today
    18.7
    Dividend yield 1yr %
    Below industry Median
    0.4

    Divis Laboratories Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Divis Laboratories Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    2585 Cr
    2319 Cr
    2338 Cr
    2118 Cr
    2303 Cr
    Divis Laboratories Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    9712 Cr
    8184 Cr
    8112.17 Cr
    9073.7 Cr
    7031.96 Cr
    5584.05 Cr
    Divis Laboratories Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    662 Cr
    589 Cr
    510 Cr
    430 Cr
    538 Cr
    Divis Laboratories Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    2191 Cr
    1600 Cr
    1823.38 Cr
    2960.45 Cr
    1984.29 Cr
    1376.54 Cr

    Divis Laboratories Result Highlights

    • Divis Laboratories Ltd reported a 0.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 18.1%.

    • Its expenses for the quarter were down by 0.4% QoQ and up 7.6% YoY.

    • The net profit decreased 8.7% QoQ and increased 67.6% YoY.

    • The earnings per share (EPS) of Divis Laboratories Ltd stood at 20.3 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Divis Laboratories

    Promoter
    51.9%
    Foreign Institutions
    18%
    Mutual Funds
    12.8%
    Domestic Institutions
    20.7%
    Public
    9.4%
    Promoter
    51.9%
    Foreign Institutions
    18%
    Mutual Funds
    11.9%
    Domestic Institutions
    20.5%
    Public
    9.6%
    Promoter
    51.9%
    Foreign Institutions
    17.2%
    Mutual Funds
    11.9%
    Domestic Institutions
    21.1%
    Public
    9.8%
    Promoter
    51.9%
    Foreign Institutions
    16.2%
    Mutual Funds
    13.1%
    Domestic Institutions
    21.7%
    Public
    10.2%
    Promoter
    51.9%
    Foreign Institutions
    14.7%
    Mutual Funds
    14.3%
    Domestic Institutions
    22.2%
    Public
    11.2%
    Promoter
    51.9%
    Foreign Institutions
    14.8%
    Mutual Funds
    13.7%
    Domestic Institutions
    21.9%
    Public
    11.3%

    Divis Laboratories Technical Analysis

    Moving Averages Analysis
    6871
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    6,739.40
    10Day EMA
    6,683.30
    12Day EMA
    6,670.90
    20Day EMA
    6,626.60
    26Day EMA
    6,588.70
    50Day EMA
    6,430.40
    100Day EMA
    6,199.60
    200Day EMA
    5,841.00
    5Day SMA
    6,705.30
    10Day SMA
    6,636.20
    20Day SMA
    6,639.80
    30Day SMA
    6,625.10
    50Day SMA
    6,426.40
    100Day SMA
    6,086.50
    150Day SMA
    6,027.30
    200Day SMA
    5,954.00
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    210946 Rs
    393929 Rs
    Week Rs
    283726 Rs
    438558 Rs
    Month Rs
    238287 Rs
    394974 Rs
    6,809.17
    Pivot
    Resistance
    First Resistance
    6,922.33
    Second Resistance
    6,988.17
    Third Resistance
    7,101.33
    Support
    First Support
    6,743.33
    Second support
    6,630.17
    Third Support
    6,564.33
    Relative Strength Index
    66.42
    Money Flow Index
    66.15
    MACD
    82.14
    MACD Signal
    77.23
    Average True Range
    134.48
    Average Directional Index
    21.56
    Rate of Change (21)
    4.86
    Rate of Change (125)
    13.42
    Name
    Holding Percent
    SBI MUTUAL FUND
    4.97
    AXIS MUTUAL FUND TRUSTEE LIMITED
    1.39
    NIPPON LIFE INDIA TRUSTEE LTD
    1.2
    GOVERNMENT OF SINGAPORE
    2.26
    GOVERNMENT PENSION FUND GLOBAL
    1.32
    LIFE INSURANCE CORPORATION OF INDIA
    5.63

    Divis Laboratories Latest News

    30 JUN 2025 | Monday

    Divis Laboratories Ltd - 532488 - Closure of Trading Window

    29 MAY 2025 | Thursday

    Divis Laboratories Ltd - 532488 - Communication To Shareholders - Information Regarding Deduction Of Income Tax At Source From Payment Of Dividend For The Financial Year 2024-25

    26 MAY 2025 | Monday

    Divis Laboratories Ltd - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    View More

    Divis Laboratories Share Price FAQs

    Divis Laboratories share price is ₹6871 in NSE and ₹6865.1 in BSE as on 1/7/2025.

    Divis Laboratories share price in the past 1-year return was 48.98. The Divis Laboratories share hit a 1-year low of Rs. 4395.3 and a 1-year high of Rs. 6875.

    The market cap of Divis Laboratories is Rs. 182018.53 Cr. as of 1/7/2025.

    The PE ratios of Divis Laboratories is 82.33 as of 1/7/2025.

    The PB ratios of Divis Laboratories is 12.2 as of 1/7/2025

    The Mutual Fund Shareholding in Divis Laboratories was 12.83% at the end of 1/7/2025.

    You can easily buy Divis Laboratories shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Divis Laboratories share price is ₹6875 and ₹4395.3 as of 1/7/2025.

    Please be aware that Divis Laboratories stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    820.30
    -0.05 (-0.01%)
    1,528.40
    +27.80 (+1.85%)
    2,012.10
    +10.60 (+0.53%)
    1,606.80
    +5.00 (+0.31%)
    3,429.70
    -32.30 (-0.93%)
    Top Gainers
    7,496.00
    +254.00 (+3.51%)
    432.25
    +10.75 (+2.55%)
    1,528.40
    +27.80 (+1.85%)
    1,862.50
    +24.20 (+1.32%)
    2,369.50
    +28.40 (+1.21%)
    Top Losers
    2,410.10
    -55.20 (-2.24%)
    1,173.30
    -25.90 (-2.16%)
    696.45
    -10.40 (-1.47%)
    261.00
    -3.15 (-1.19%)
    6,144.00
    -73.50 (-1.18%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -